Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Either way from current prices the potential reward v. speculative risk is outstanding, IMO.
A scenario where they get a significant cash payment upfront to acquire the KRM-II-81 program with milestone payments could be ideal if they intend to list on a higher exchange where they can obtain institutional investment support and use the funds to further the other drug development programs, while hopefully the KRM-II-81 successfully hits milestones in the human clinicals that will then continue to add enormous value in subsequent quarters.
IF the tier 3 NIH preclinicals are successful, my opinion is a development deal is a slam dunk and the company has no business hanging out on the OTC exchange with other promising development programs in the works.
Yet here we are speculating while the company is radio silent with no 10-k filing, yet gets a cash infusion from BOD member?. Feels like a storm is brewing, just dont know if it will wipe us out or be electric and send this to nickels and dimes... OTC casino at the finest... Good luck to us all.
i agree, have been through a buyout with milestones before, after the buyout, the shareprice sank, because the milestones were months to years away. lesson learned. SELL after buyout if there are milestones involved
Yeah but the only problem with a immediate buyout is shareholders may not feel impact of hitting milestones and the huge market cap increase that comes as drugs are closer to market…
If a cash payment to acquire the drug platform was plenty sufficient, there would be plenty of money to eliminate any further debt and dilution and excess cash could be utilized to further other platforms while listing higher exchange could bring institutional support while waiting for milestones and chunk payments to come in.
All speculation but that is the fun of the OTC. Would love to hear status update and forward plans from the company….
A buyout resolves the funding forward for maximum efficacy, though, versus a rs delays forward progress, and there is more upside to quickly going forward than a rs could offer given these drugs combined easily represent billions in profit sooner than later?
Or are a rs and a buyout comparable in their Tyractiveness to a BP buyer?
the only downside to that scenario is the question of how they get to a higher exchange. the worse case is a RS. i have seen pumpers try to explain how a RS could be positive for the company and in every case it destroys the shareholder's leverage. The sole reason for buying shares on the cheap is the amount of leverage it supplies to a shareholder. So let us Pray that that does NOT happen here. The best case scenario is a buyout. It Rewards the shareholder for their early on Faith in a company. A RS means that you as a shareholder were "used" as a mere place holder, and the leaders of the company is using you, stringing you along with bs tweets, youtube videos etc... and they are more focused on paying the bills than rewarding its shareholders. BUYOUT is the only way, let BP take on the risk, not us mini-angel investors
I have seen where many pharma deals get structured as such. Cash up front and then boatloads more cash as the continued development efforts hit further milestones.
With the lack of 10-k, and complete silence from the company, it feels like "maybe" some negotiations are on the table currently. That is all pure speculation, but as discussed here, OSA preclincals and the NIH tier 3 preclinicals should be advancing to some stage to now know if ready to launch into human clinical trials.
I highly doubt too that BP would want to deal with OTC shenanagins, so possibly/hopefully any type of deal would also include plans to trade on a higher exchange. This alone would significantly help support the other drug development programs. Either way, when some equity is valued at a mere 1 million and has pharma asset appreciation potential into the 100's of millions with market potential into the billions, there is some upside in the risk v reward equation!
Could a BP be negotiating a deal with a minimum initial purchase price with additional future payments ...IF...certain efficacy emerges and translates into sales?
Am thinking Mark Cuban on Sharktank...offering a set initial price plus % more if certain tiers are met.
Schmuck insurance being current investors are bought out only at 90-95%....or less?
I hope this stays in the trips for a couple more weeks I want to load the …. Out this. One of the Easiest 20-50 bagger plus I’ve ever seen!
Huge buys VS. Little sells, high volume, trend is for a few days higher sp with high volume = momentum.
Let word of mouth over the weekend increase the trend
from friendly to friend!
More coming in now..strange with OTCN staying put.
Interesting... What is up with all these $10-$20 share lots... market makers getting itchy?
Most popular boards means eyes on the stock. https://investorshub.advfn.com/boards/breakoutboards.aspx
What does that mean?
~10000 share transactions every ~5 seconds for a while around 11am.
RSPI 11 million bid and only OTCN on the ask..we need some ask slapping.
$RSPI #2 on breakout boards
I’m with you brother! Waiting and ready… have a great one Sharky.💪🏻👊🏻
Well, I think their filings has continued to state they plan to license, JV/partner or sell all their assets at some point in development. There obviously is not the depth in people or money resources to go this alone. In that context, it does make the lack of 10-k and silence interesting. Have to wonder if there is some type of negotiations ongoing that places those items on the backburner.
GM all starting to gain traction here, build the strength.
$RSPI
Nice analogy i luv Freebird!!..This bird will fly soon.
Big Pharma Company may be able to Buyout this company for $2.50- $5.00/Share buy why would they today?
They can just start loading up shares now for pennies on the dollar if they wanted.
Let them help run up this stock where it should be.
Drug companies are not buying out drug companies in 2024, or are they!
2024 Pharmaceutical Industry Mergers & Acquisitions Roundup
Ampersand Capital Partners—Biologos LLC. ...
AstraZeneca—Fusion Pharmaceuticals. ...
Bristol Myers Squibb—Karuna Therapeutics. ...
AstraZeneca—Amolyt Pharma. ...
Novartis—IFM Due. ...
Johnson & Johnson—Ambrx. ...
Eilean Therapeutics—Ness Therapeutics. ...
CoreRx—Societal CDMO.
Is there big money in drugs?
Here are the 10 projected best-selling drugs in 2024 and their expected global sales:
Keytruda (Merck) — $27.2 billion.
Ozempic (Novo Nordisk) — $16.1 billion.
Dupixent (Sanofi) — $13.5 billion.
Eliquis (Bristol Myers Squibb) — $13.3 billion.
Biktarvy (Gilead) — $12.6 billion.
Darzalex (Johnson & Johnson) — $12 billion.
Others
https://seekingalpha.com/article/4679123-3-potential-biotech-buyout-targets-in-2024
Right on. RSPI HEATING UP
Them other companies are getting those kinds of prices
Well stated!!!
To see how far fetched it may or may not be…
Drug stocks go from one extreme to the other and bounce around depending on news and filings.
Look at JAGX it is on NASDAQ it keeps up with filings, it was struggling to not get delisted to the OTC markets for low share price under 10 cents, it hit 5 cents. They were waiting for a phase 3 results that have been delayed and delayed but they got an extension to stay on Nasdaq.
Well they have gone from 5 cents to .3389 but the one year high was $1.22 and it may be heading past the 52 week high with Drug news or results.
RSPI needs to get to .0067 before it can even think of $1 RSPI 52 week high was .0191
While it is not out of reach, lets get to a penny 1st
To get RSPI moving up they need to file the late 10k to get Pink Current.
KRM-II-81 is a game changer and could very much get us our golden nest eggs. ⭐️🌟🏆🌟⭐️
.0191 would be nice to see again.
With the various IP's and the specific Pipelines we hold, I would venture to say that a Big Pharma Company would Easily be able to Buyout this company for $2.50- $5.00/Share. this little Gem is small yet playing in the major League of BP's. It is like they are a group like Lynyrd Skynyrd opening for The Who back in the day, nobody really heard of them, however, when they played a show people knew they were the Real Deal and were soon in high demand!!!
Hang on to your shares, when this hits, it is going to soar!!!
Buyout or Merger or Partnership is not out of the question!!!
More of the same tomorrow.Word seems to be getting out.
If this all goes well there is potential for $1.00s here, seems far fetched but it’s really not.
Nice solid move up into the .00s today
Nice accumulation today, over 7-1, looking ready.
$RSPI
More press.
Mild Cognitive Impairment Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics
05-02-2024 08:01 PM CET | Health & Medicine
Press release from: DelveInsight Business Research
“• Key Mild Cognitive Impairment Companies: FUJIFILM Toyama Chemical Co. Ltd., Aptinyx, AgeneBio, Eisai Inc., RespireRx, Allon Therapeutics, CuraSen Therapeutics, Inc., Avraham Pharma, AstraZeneca, Sage Therapeutics, Pfizer, Materia Medica Holding, Eli Lilly and Company, GE Healthcare, Parexel, and others
• Key Mild Cognitive Impairment Therapies: T-817MA, NYX-458, Aptinyx, T-817MA, Aricept (donepezil hydrochloride), CX516, AL-208, CST-2032, ladostigil hemitartrate, AZD5213, SAGE-718, fesoterodine, MMH-MAP, Donanemab, Flutemetamol (18F) Injection, EVP-0962, and others “
“Mild Cognitive Impairment Therapies and Key Companies
• T-817MA: FUJIFILM Toyama Chemical Co. Ltd.
• NYX-458: Aptinyx
• Aptinyx: AgeneBio
• T-817MA: FUJIFILM Toyama Chemical Co., Ltd.
• Aricept (donepezil hydrochloride): Eisai Inc.
• CX516: RespireRx
• AL-208: Allon Therapeutics
• CST-2032: CuraSen Therapeutics, Inc.
• ladostigil hemitartrate: Avraham Pharma
• AZD5213: AstraZeneca
• SAGE-718: Sage Therapeutics
• fesoterodine: Pfizer
• MMH-MAP: Materia Medica Holding
• Donanemab: Eli Lilly and Company
• Flutemetamol (18F) Injection: GE Healthcare
• EVP-0962: Parexel“
https://www.openpr.com/news/3483246/mild-cognitive-impairment-market-to-observe-impressive-growth
Looking better here, loaded more 9s on dip,patience play
That was a non literal expression of surprise, not lack of understanding
Huh?!
P.T. Barnum said you can never go broke underestimating the intelligence of the American public.
Nowadays that translates into:
You can never go broke underestimating the CONSCIOUSNESS of the public.
Increased brain fog, increased dopamine from avid scrolling of computer and cell phone screens, etc.
Seems our brains are being chemically tittalated whilst weaving in and out of the brain fog.
Well, as long as enough of the people can be fooled enough of the time, we will be in a temporarily insufficient state of awareness.
As we emerge from that state, if we have opportunity within which to do so....Star Trek?
Thanks for the article recommendation.
Correct, you have to leverage a big numbers game. Mitigating “hit-and-miss” with brute force, tolerance to risk, and ignoring the urge to short-term profit at the detriment of long-term progress. It’s a necessary, deliberate choice of strategy.
From my perspective if you are putting together an archery team, you select the members based upon who is closest to the bullseye. Hence why you see many preclinical and early clinical development deals. BP can afford a few misses as long as they get one that nails the bullseye in company making fashion.
You make a very good point. Hence why some would consider this gambling like most OTC or speculative stocks/industries.
Odds of scoring a touchdown in pharma industry is low; RSPI in some sense just needs to get the ball in field goal range.
A recent PR suggested they were waiting to maybe later in the year to pursue further the SCI/ADHD program. OSA program has many others seeking that solution as well as questions around utilizing cannibas or synthetic related compounds. They have given the impression they are doing preclinicals there, but no recent update.
The pain/epilepsy candidate feels just a bit different to me. I think NIH has an important/meaningful task in regards to opioids that bypasses the shenangins within the majority of the political arena. The confidence and excitement, and commentary from outside reputable perspectives in regards to progress with epilepsy and pain on this candidate I think is hard for them to mask. It is hard for retail positions to gauge progress, but I kinda feel they have completed a few first downs and are driving the ball.... IMO
Developing drugs that are actually useful for helping mental, psychological, emotional problems is a bit like being a blind sniper! So there’s a reason Big Pharma is floundering, generally. Huge uncertainty, and basic problems with statistical methods means that you can’t design such treatment like you would design a car, or an airplane. It requires much more “groping in the dark”.
If you are up for a challenging, but accessible account of some of origins of the disconnection that currently plagues basic neuroscience, and the medical/psychiatry toolkit that is obviously largely not living up to it’s potential, try this!:
https://www.wsj.com/articles/the-world-behind-the-world-review-what-the-brain-scan-misses-6033e7ad
1. Given the nefarious recent history of scientific research being a deliberate sham to get government funding...some say as much as 99% of it
2. Obviously earned distrust of pols by non pols, extending sometimes to alphabet govt. Agencies...no disregard for govt. Workers...
3. Given the nefarious history of OTC stocks as a pump and dump...repeat...territory
Is it possible so many are jaded and just doubtful of such a government agency [nih], aiding an effort for a non-opiode pain disintegrating drug...
"REALLY?...AND BIG PHARMA WILL BE OKAY WITH ONLY ONE BP WINDING UP WITH THIS UNTIL GENERICS CAN MAKE THE SCENE"...I hear some saying in my imagination.
"Oh! And a drug to replace sleep apnea machines and constant flow of cpap machine supplies, too?"
"OH, and an anti-convulsant for epilepsy sufferers with no side effects and more?!?!"
"Please tell me there is a bridge in Brooklyn as an extra added asset for which tolls can be charged?"
Just researching all of the sham in the arenas that RSPI is in, presumably with integrity makes e1 but a few of us already invested, looking and waiting b4 jumping in?
It really does sound too good to be true, doesn't it?
And the proof of the pudding is in the tasting, isn't it?
Just waiting for it to be sufficiently tasted.
We are a true minority of invested believers.
Is RSPI the only penny stock?
New May 2, 2024 mention of RespireRx RSPI:
Spinal Cord Injury Therapeutics Market See Incredible Growth 2024-2031 | Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc
05-02-2024 01:57 PM CET | Health & Medicine
Press release from: Coherent Market Insights
“Key Players Covered In This Report:
Teva Pharmaceutical Industries Ltd., AbbVie Inc, Pfizer Inc., Reddy's Laboratories Ltd, Zydus Cadila, ReNetX Bio, Inc, InVivo Therapeutics Holdings, Lineage Cell Therapeutics, Inc, Kringle Pharma, Inc., Acorda Therapeutics, Inc., Bioaxone Biosciences, Inc, RespireRx Pharmaceuticals Inc., NervGen, Rising Pharmaceuticals, Inc, ScieGen Pharmaceuticals, Inc, MSN Laboratories Private Limited, and Lannett Co Inc.”
https://www.openpr.com/news/3482860/spinal-cord-injury-therapeutics-market-see-incredible-growth
Well with minimal liquity on most OTC equities, the movement of the MM's is really just on a whim here and there and a few traders with small money interest can influence. So IMO, nothing real can be gleened from that with minimal volume.
I think the investment thesis here is rather simple. Either you are long and believe in the possibilities of their drug programs and current progress setting up for BP or similar deals, or you don't. If they cant create value with their programs then this flounders. If they do create valuae and strike a major deal, this will be a hard one to catch and will be one of those long rememebered story stocks of the OTC. IMO.
Moved up but still hanging around...gotta get big volume.
OTCN parked at .0009...smh.
Interesting oldstocks.. thanks !! for all you do in every board buddy.
Followers
|
279
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
45303
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody fly_fisherman jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |